Alluzience 200 units/ml injectable solution
Prescription request online
A doctor will review your case and decide whether a prescription is medically appropriate.
Talk to a doctor about this medicine
Discuss your symptoms and possible next steps in a quick online consultation.
How to use ALLUZIENCE 200 Units/mL Injectable Solution
Contents of the leaflet
- Introduction
- What is Alluzience and what is it used for
- What you need to know before using Alluzience
- How to use Alluzience
- Possible side effects
- Storage of Alluzience
- Contents of the pack and further information
Introduction
Leaflet: information for the patient user
Alluzience, 200 units Speywood/ml, injectable solution
Botulinum toxin type A from Clostridium botulinum– hemagglutinin complex
Read the entire leaflet carefully before starting to use this medicine, as it contains important information for you.
- Keep this leaflet, as you may need to read it again.
- If you have any questions, consult your doctor.
- If you experience side effects, consult your doctor, even if they are not listed in this leaflet. See section 4.
Contents of the leaflet
- What is Alluzience and what is it used for
- What you need to know before starting to use Alluzience
- How to use Alluzience
- Possible side effects
- Storage of Alluzience
- Contents of the pack and further information
1. What is Alluzience and what is it used for
Alluzience contains a substance, botulinum toxin A, which causes muscles to relax. Alluzience acts on the connection between nerves and muscles, blocking the release of a chemical messenger called acetylcholine at the nerve endings. This phenomenon prevents muscle contraction. Muscle relaxation is temporary and gradually recovers.
Some people feel unwell when wrinkles appear on their face. Alluzience can be used in adults under 65 years of age for the temporary improvement of the appearance of moderate to severe glabellar lines (vertical expression lines between the eyebrows).
Not sure if this medicine is right for you?
Discuss your symptoms and treatment with a doctor online.
2. What you need to know before using Alluzience
Do not use Alluzience:
- if you are allergic to botulinum toxin A or any of the other components of this medicine (listed in section 6).
- if you have an infection at the sites where you plan to inject.
- if you have severe myasthenia, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis.
Warnings and precautions
Consult your doctor before starting to use this medicine:
- if you have any neuromuscular disorder
- if you often have difficulty swallowing (dysphagia)
- if you often have problems with food or drink entering your airways, causing choking or coughing
- if you have any inflammation at the proposed injection site
- if the muscles where you will be injected are weak or show signs of atrophy
- if you have any coagulation disorder, which means you may bleed more than normal, such as hemophilia (hereditary bleeding disorder caused by coagulation factor deficiencies)
- if you have undergone or will undergo facial surgery or other surgery
- if you did not experience any improvement in your glabellar lines after your last treatment with botulinum toxin
This information will help your doctor make a decision about the risks and benefits of your treatment.
Special precautions:
Very rare side effects have been reported with botulinum toxin, possibly related to the spread of the toxin effect to areas away from the injection site (e.g., muscle weakness, difficulty swallowing, or unwanted food or liquids in the airways). Seek medical attention immediately if you have difficulty swallowing, speaking, or breathing.
When using Alluzience in the muscles around the eye, your eyes may become dry, which can damage the surface of your eyes. To avoid this, you may need treatment with protective drops, ointments, or a protective cover that closes the eye. Your doctor will tell you if this is necessary.
When botulinum toxin has been used at more frequent intervals of 3 months or at higher doses to treat other conditions, the production of antibodies has been observed infrequently. The formation of neutralizing antibodies can reduce the effectiveness of treatment.
If you visit your doctor for any reason, make sure to inform them that you are being treated with Alluzience.
Children and adolescents
Alluzience is not indicated for patients under 18 years of age.
Other medicines and Alluzience
Tell your doctor if you are taking, have recently taken, or may take any other medicine. This is important because some of these medicines can increase the effect of Alluzience:
- antibiotics to treat an infection (e.g., aminoglycosides such as gentamicin or amikacin), or
- other muscle relaxants.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor before using this medicine.
Alluzience should not be used during pregnancy or breastfeeding.
Driving and using machines
You may experience blurred vision or temporary muscle weakness after treatment with Alluzience. If this occurs, do not drive or use machines.
Alluzience contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per vial, which is essentially "sodium-free".
3. How to use Alluzience
Alluzience can only be administered by doctors with the necessary qualifications and experience in this treatment and who have the necessary equipment.
Your doctor will apply the injections. A vial of Alluzience should be used for a single patient and a single treatment session.
The recommended dose for glabellar lines is 50 units Speywood, administered as 10 units in each of the 5 injection sites on the forehead, at the top of the nose, and eyebrows.
The recommended doses in Speywood units are different from other botulinum toxin preparations.
The effect of the treatment should be noticeable a few days after the injection and can last up to 6 months.
Your doctor will decide on the appropriate interval between each treatment with Alluzience. This interval should not be less than 3 months.
Use in children and adolescents
Alluzience is not indicated for patients under 18 years of age.
If you use more Alluzience than you should
If you receive more Alluzience than necessary, other muscles different from those treated may begin to weaken. Excessive doses can cause paralysis of the respiratory muscles. This may not occur immediately. If these symptoms appear, inform your doctor as soon as possible.
In cases of overdose or accidental administration, call the Toxicology Information Service, phone 91 562 04 20 (indicating the medicine and the amount administered).
If you have any other questions about the use of this medicine, ask your doctor.
Started taking the medicine and have questions?
Discuss your symptoms and treatment with a doctor online.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everyone gets them.
Very rarely (may affect up to 1 in 10,000 people), side effects have been reported with botulinum toxin in muscles other than those at the injection site. These effects include excessive muscle weakness, difficulty swallowing, coughing, and a feeling of choking when swallowing (if liquids or food enter the airways when trying to swallow, respiratory problems such as pneumonia can occur). If this happens, inform your doctor immediately.
Seek urgent medical attention if:
- You experience difficulty breathing, swallowing, or speaking
- Your face swells or your skin turns red, or you have a rough rash with itching. You may be suffering an allergic reaction to Alluzience.
Tell your doctor if you experience any of these side effects:
Very common (may affect more than 1 in 10 people)
- Headache
- Reactions at the injection site (such as pain, tingling, bruising, redness, swelling, itching, rash, irritation, discomfort, stinging), generalized weakness, fatigue, and flu-like symptoms.
Common (may affect up to 1 in 10 people)
- Temporary facial paralysis
- Drooping of the upper eyelid, swelling of the eyelid, drooping of the eyebrow, eye fatigue, or decreased vision, dry eye, contraction of the muscles around the eye, tearing.
Uncommon (may affect up to 1 in 100 people)
- Eyelid twitching, vision changes, blurred or double vision
- Ocular allergy, hypersensitivity, rash.
Frequency not known (cannot be estimated from available data)
- Numbness
- Muscle mass loss
Reporting side effects:
If you experience any side effects, consult your doctor, even if they are not listed in this leaflet. You can also report them directly through the Spanish Medicines Monitoring System: https://www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
5. Storage of Alluzience
Keep this medicine out of the sight and reach of children.
Do not use Alluzience after the expiration date stated on the label.
Store Alluzience in the refrigerator (2°C - 8°C). Do not freeze. Keep the vials in the original packaging to protect them from light.
After removing the vial from the refrigerator, it is recommended to let the vial reach room temperature. Alluzience can be stored at temperatures up to a maximum of 25°C for a single period of 12 hours without opening and protected from light. Alluzience should be discarded if not used within 12 hours after removal from refrigeration.
Once opened, the product must be used immediately.
6. Contents of the pack and further information
Composition of Alluzience
The active substance is botulinum toxin type A*, 200 units Speywood/ml. One vial contains 125 units Speywood in 0.625 ml of solution.
The other components are: L-histidine, sucrose, sodium chloride, polysorbate 80, hydrochloric acid, water for injectable preparations
*Botulinum toxin type A from Clostridium botulinum(a bacterium) – hemagglutinin complex.
The units of botulinum toxin are not interchangeable from one product to another. The recommended doses in Speywood units are different from other botulinum toxin preparations.
Appearance of the product and pack contents
Alluzience is an injectable solution. It comes in a single pack of 1 or 2 vials or in a multipack containing 6 single packs, each containing 2 vials. Not all pack sizes may be marketed.
Alluzience is a clear and colorless solution.
Marketing authorization holder and manufacturer
Marketing authorization holder:
Ipsen Pharma
65 quai Georges Gorse
92100 Boulogne-Billancourt
France
Manufacturer:
Ipsen Manufacturing Ireland Limited
Blanchardstown Industrial Park
Blanchardstown
Dublin 15
Ireland
You can request more information about this medicine by contacting the local representative of the Marketing Authorization Holder:
Local representative:
Laboratorios Galderma SA
Serrano Galvache, 56.
28033 Madrid - Spain
Phone: 902 02 75 95
Date of last revision of this leaflet:November 2022
Other sources of information
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.
-----------------------------------------------------------------------------------------------------------------
This information is intended only for healthcare professionals:
Posology and method of administration:
See section 3 of the Patient Information Leaflet.
Special precautions for disposal and other handling
Instructions for use, handling, and disposal must be strictly followed.
RECOMMENDATIONS FOR THE DISPOSAL OF CONTAMINATED MATERIALS
Immediately after patient treatment, any unused Alluzience (in the vial or syringe) should be inactivated with a diluted sodium hypochlorite solution (bleach) (1% available chlorine).
Any spilled Alluzience should be cleaned with an absorbent cloth soaked in a diluted sodium hypochlorite solution.
Used vials, syringes, and materials should not be emptied and should be disposed of in appropriate containers and eliminated according to local requirements.
RECOMMENDATIONS IN CASE OF ACCIDENT DURING HANDLING OF BOTULINUM TOXIN
- Any remaining product should be cleaned with a dry absorbent material.
- Contaminated surfaces should be cleaned with an absorbent material soaked in a sodium hypochlorite solution (bleach) and then dried.
- If a vial is broken, proceed as indicated above, carefully collecting the glass fragments and cleaning the product, avoiding cuts with the broken glass.
- If the product comes into contact with the skin, wash the affected area with a sodium hypochlorite solution (bleach) and rinse with plenty of water.
- If the product comes into contact with the eyes, rinse carefully with plenty of water or an eye cleaning solution.
- If the product comes into contact with a wound, cut, or broken skin, rinse carefully with plenty of water and take appropriate medical measures according to the injected dose.
These instructions for use, handling, and disposal must be strictly followed.
Illustrative image - Country of registration
- Dosage formINJECTABLE, 200 U/ml
- ATC codeM03AX01
- Active substance
- Prescription requiredYes
- Manufacturer
- CompositionSACAROSA (2,5 mg/ml mg), CLORURO DE SODIO (5,48 mg/ml mg), POLISORBATO 80 (0,06 mg/ml mg)
- This information is for reference only and does not constitute medical advice. Always consult a doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to ALLUZIENCE 200 Units/mL Injectable Solution
AZZALURE 125 units SPEYWOOD powder for injectable solutionIllustrative imageDosage form: INJECTABLE, 125 Speywood UnitsActive substance: botulinum toxinManufacturer: Ipsen Pharma S.A.U.Prescription required
BOCOUTURE 100 units powder for injectable solutionIllustrative imageDosage form: INJECTABLE, 100 unitsActive substance: botulinum toxinManufacturer: Merz Pharmaceuticals GmbhPrescription required
BOCOUTURE 50 units powder for injectable solutionIllustrative imageDosage form: INJECTABLE, 4 units/ 0.1 mlActive substance: botulinum toxinManufacturer: Merz Pharmaceuticals GmbhPrescription required
Online doctors for ALLUZIENCE 200 Units/mL Injectable Solution
Discuss questions about ALLUZIENCE 200 Units/mL Injectable Solution, including use, safety considerations and whether a prescription is appropriate, subject to medical assessment and local regulations.
Frequently Asked Questions
ALLUZIENCE 200 Units/mL Injectable Solution requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
The active ingredient in ALLUZIENCE 200 Units/mL Injectable Solution is botulinum toxin. This information helps identify medicines with the same composition but different brand names.
ALLUZIENCE 200 Units/mL Injectable Solution is manufactured by Ipsen Pharma. Pharmacy brands and packaging may differ depending on the distributor.
Doctors such as Endocrinologists, Rheumatologists, Neurologists, General medicine doctors may assess whether ALLUZIENCE 200 Units/mL Injectable Solution is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
The prescription is issued by a doctor after assessing your health. In Spain, ALLUZIENCE 200 Units/mL Injectable Solution is then dispensed in pharmacies with that prescription. An online consultation does not guarantee that a prescription will be issued: the decision always rests with the doctor.
To request an assessment, you can use Oladoctor:
Other medicines with the same active substance (botulinum toxin) include AZZALURE 125 units SPEYWOOD powder for injectable solution, BOCOUTURE 100 units powder for injectable solution, BOCOUTURE 50 units powder for injectable solution. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
